Sign Up for a Free Account

This is an image preview.
Start a Free Account
to view the full image.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Evidence-based medicine measures calculated from published trials of interferon beta in relapsing-remitting multiple sclerosis or first clinically isolated syndromes suggesting multiple sclerosis

Risk ratio (RR), absolute risk reduction (ARR) of adverse outcomes (conversion to clinically defined multiple sclerosis, relapse, progression, or MRI activity), and numbers needed to treat (NNT) to prevent the adverse outcomes have been calculated for the multicenter randomized controlled trials (references indicated between parenthesis in table second row) according to intention-to-treat analysis principles (patients lost to follow-up or who stopped treatment taken as adverse outcomes, if not differently reported) on 2-year results except when indicated. (Contributed by Dr. Luca Durelli.)

Related Media